It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
We tailor every screen to your molecule’s needs—considering route, dose, and physicochemical profile—then apply advanced techniques and analytics to confirm form generation and performance.
Selecting the right salt and co-crystal enhances API properties, improving solubility, stability, and crystallinity while adding strategic IP value.
Our salt and co-crystal screening services are designed to enhance key physicochemical properties such as dissolution, thermal stability, and crystallinity. These modifications not only improve performance but also offer a valuable route to strengthen your intellectual property.
While salt formation is often the preferred choice for IP protection, the crystalline nature of salts is not always guaranteed. Identifying and confirming crystalline salts can significantly increase the value of your program by combining performance with patentability.
Designing a Screen
We tailor every screen to your molecule’s characteristics, route, and dose. Then we validate performance using the right analytics to guide confident decisions.
Inputs
We begin with a clear understanding of your molecule:
• pKa and ionization behavior
• Intended route of administration
• Expected dose/target exposure
• Solubility & stability constraints
• Any manufacturability requirements
Screen Execution
Our screening process includes:
• Phase appropriate counter-ion and co-former selection
• Crystallization traials and isolation
• Orthogonal confirmation using XRPD, DSC, TGA, DVS and PLM
• Verification of salt formation and stoichiometry via multinuclear NMR and FT-IR
Outputs & Deliverables
You’ll receive:
• Solubility in relevant media
• Dissolution profiles using Pion μDISS or μFLUX where needed
• Stability data under ICH-conditions (25°C/60%RH and 40°C/75%RH)
• Ranked recommendations with clear next steps for formulation and IP strategy
Properties You Can Modify
Salt and co-crystal screening can help you:
• Convert an amorphous drug substance to a crystalline salt
• Improve thermal stability through ionic salt formation
• Modify hygroscopicity to control moisture uptake
• Enhance solubility-often the key driver for salt selection
• Adjust crystal size & morphology for easier isolation and drying
• Explore new polymorphic landscapes distinct from the free API
• Improve mechanical properties for milling, flow, compressibility, and density
Why Choose Sygnature Discovery for Salt and Co-Crystal Screening Support?
Solid form selection is a critical step in drug development. Our approach combines scientific rigor, flexibility, and collaboration to ensure your molecule is optimized for performance, manufacturability, and regulatory success.
Here’s what sets us apart:
• Integrated Expertise: Our multidisciplinary team brings together deep knowledge in solid-state chemistry, thermal analysis and formulation science.
• Tailored Screening Strategies: We design bespoke protocols using a diverse library of pharmaceutically acceptable counterions and co-formers, aligned with your molecule’s physicochemical profile, route and dose.
• Advanced Characterization Capabilities: We use XRPD, thermal analysis, microscopy, and spectroscopy to generate comprehensive data that supports confident decision-making.
• End-to-End Support: Whether you’re in early discovery or preparing for clinical development, our services integrate seamlessly with your broader development strategy.
Delve into the realm of targeted protein degradation and the critical role of formulation strategies in drug development. From overcoming dissolution limitations to optimizing stability and solubility, explore the key components that ensure your molecule’s clinical success. Sygnature Discovery offers comprehensive formulation support, bringing your degrader one step closer to achieving its full potential.
Sygnature has announced the set-up of a state-of-the-art Early Candidate Developability Screening Group. Located at…
News
FAQs
Salt and co-crystal forms can significantly improve a compound’s solubility, stability, bioavailability, and manufacturability – key factors for successful formulation and clinical progression.
Ideally during lead optimization or early preclinical development, but it can also be valuable later when solubility or stability issues arise.
We typically require the chemical structure, physicochemical data (e.g., solubility, pKa), and any known formulation or stability challenges. We’ll guide you through the rest.
We use a rational selection process based on regulatory acceptability, molecular complementarity, route of administration and physicochemical properties.
We employ XRPD, DSC, TGA, microscopy, FTIR / NMR and HPLC among others, to confirm identity, purity, and solid-state properties.
Yes. We offer in vivo pharmacokinetic studies and bioavailability assessments to support candidate selection and formulation decisions.
Possibly. A bridging study may be required if the salt form alters pharmacokinetics or safety profiles. We can support you with DMPK assessments and PBPK modelling to evaluate this.
Related Solutions
We bring together a dynamic blend of new talent and experienced pharmaceutical industry experts from a round the world, delivering excellence across every stage of discovery.
DMPK
Integrated DMPK solutions combining advanced assays, modeling, and bioanalysis delivering predictive insights that reduce risk and guide candidate selection.
Validated in vivo models deliver clinically relevant data across therapeutic areas, accelerating confident decisions and reducing risk in drug development.
